TX45
Heart Failure with Preserved Ejection Fraction (HFpEF) and other fibrotic diseases
Key Facts
Indication
Heart Failure with Preserved Ejection Fraction (HFpEF) and other fibrotic diseases
Phase
Phase 1
Status
Active, Recruiting
Company
About Tectonic Therapeutic
Tectonic Therapeutic is advancing a pipeline of protein therapeutics designed to modulate large, multi-subunit targets like GPCRs, which have historically been challenging for drug discovery. The company's lead program, TX45, is a selective inhibitor of the relaxin receptor RXFP1, currently in Phase 1 trials for cardiovascular and fibrotic indications. Founded by world-renowned scientists and backed by leading life science investors, Tectonic leverages its unique GEODe™ platform to unlock new therapeutic opportunities in areas of high unmet medical need.
View full company profile